Skip to main content
NeuroWiki
Trial

INTERACT4 Trial: Prehospital Blood-Pressure Reduction Before Stroke Type Is Known

In patients with suspected acute stroke and hypertension managed in the ambulance, does initiating intensive IV blood-pressure reduction before imaging diagnosis improve functional outcome at 90 days?

INTERACT4 Investigators (NEJM 2024) · doi:10.1056/NEJMoa2314741 · 2404 patients

Population

Included

  • Age 18 or older
  • FAST score ≥2 with arm motor deficit
  • Systolic BP ≥150 mm Hg
  • Treatment initiation within 2 hours of onset or last known well

Excluded

  • Coma or severe comorbidity
  • Epilepsy, recent head injury, or hypoglycemia
  • Inability to confirm eligibility or initiate treatment within 2 hours

Primary Outcome — mRS Distribution at 90 Days

Undifferentiated stroke (all patients)

Intensive BP Reductionn=1205
13.8%
19%
7.9%
14%
11.1%
11.6%
22.5%
Usual Caren=1199
16.1%
16.3%
6.3%
14.8%
10.9%
13%
22.6%
Shift in distributioncOR 1.00(95% CI 0.87–1.15)
Not significant

Study Arms

Agent
Urapidil (an intravenous alpha-1 adrenoceptor antagonist with 5-HT1A agonist activity, widely used in China)
Dose
Intravenous bolus of 25 mg over 1 minute, repeated once after 5 minutes if blood pressure remained elevated
Route
IV
Frequency
Bolus, repeatable once at 5 minutes; further treatment with urapidil or another agent (bolus, infusion, or oral) continued in the emergency department, stroke unit, or monitored facility
Duration
Started in the ambulance and maintained until hospital arrival
Co-interventions
Patients kept horizontal with blood pressure monitored every 5 minutes during transport. In-hospital blood-pressure management and other care per established local guidelines (China: target systolic <140 mm Hg for hemorrhagic stroke, 140 to 160 mm Hg for ischemic stroke).

Goal systolic blood pressure 130 to 140 mm Hg within 30 minutes, maintained until arrival at the hospital. A systolic blood pressure of 130 mm Hg was the threshold for cessation of treatment. Source: Li NEJM 2024 p.1864.

Trial Design

Type

  • Randomized, open-label, blinded-endpoint trial
  • Ambulance-based blood-pressure lowering before imaging diagnosis
  • Undifferentiated stroke population with SBP >=150 mm Hg within 2 hours

Timeline

China; prehospital acute stroke network

N

2404

Enrollment

Randomized Mar 2020 to Aug 2023 at 51 hospitals in China. Open-label, blinded endpoint (PROBE design).

Bedside Pearl

Type-blind prehospital BP lowering is a zero-sum strategy: you help your hemorrhagic strokes and hurt your ischemic strokes in roughly equal measure. The overall null result is not reassurance that early BP reduction is safe across the board. Without imaging to confirm stroke type, aggressive prehospital BP reduction is not routinely indicated.

NeuroWiki is a clinical reference. It does not substitute for your clinical judgment, current guidelines, or your institution's protocol. Verify before acting. Do not enter patient names, MRNs, or dates of birth. Privacy Policy